PMID- 32095285
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2090-1267 (Print)
IS  - 2090-1275 (Electronic)
IS  - 2090-1267 (Linking)
VI  - 2020
DP  - 2020
TI  - Effect of Interleukin and Hepcidin in Anemia of Chronic Diseases.
PG  - 3041738
LID - 10.1155/2020/3041738 [doi]
LID - 3041738
AB  - BACKGROUND: Anemia of chronic disease (ACD) also termed as the anemia of 
      inflammation has been found to be associated with inflammations, chronic 
      infections, and cancers, particularly in old age. Recent studies revealed that 
      interleukin-6 (IL-6), a proinflammatory cytokine, and hepcidin, an antimicrobial 
      hepatic peptide, play a key role in ACD pathogenesis. Patients and Methods. The 
      study included 40 subjects with chronic diseases and 40 normal subjects of the 
      same age group. Red cell indices, levels of IL-6 and hepcidin, and iron profile 
      were measured in all participants using Bayer ADVIA 120, VITROS 5600, Integrated 
      System/2008, and ELISA assay, respectively. RESULTS: The level of hemoglobin was 
      considerably less in patients of chronic diseases referred to as "cases" than the 
      normal subjects or "controls" (8.7 +/- 1.5 vs. 13.2 +/- 0.9). Red blood corpuscle 
      (RBC) count, hematocrit (HCT) level, serum iron, mean corpuscular hemoglobin 
      concentration (MCHC), and serum total iron-binding capacity (TIBC) were found to 
      be significantly lower in the cases as compared to controls (p < 0.001). Serum 
      IL-6 and hepcidin levels were substantially higher in the cases than in the 
      controls (p < 0.001). Serum IL-6 and hepcidin levels were substantially higher in 
      the cases than in the controls (p < 0.001). Serum IL-6 and hepcidin levels were 
      substantially higher in the cases than in the controls (. CONCLUSION: This study 
      detected a significant increase in serum IL-6 and hepcidin levels in patients 
      with ACD than the controls. These findings offer an insight into the role played 
      by both cytokine and peptide in the pathogenesis of ACD and thus provide a 
      rationale for future use of novel drugs inhibiting their effects on iron 
      metabolism.
CI  - Copyright (c) 2020 Maha F. Yacoub et al.
FAU - Yacoub, Maha F
AU  - Yacoub MF
AD  - Internal Medicine and Clinical Hematology, Faculty of Medicine, Cairo University, 
      Giza, Egypt.
FAU - Ferwiz, Hala Fouad
AU  - Ferwiz HF
AD  - El-Sahel Teaching Hospital, General Organization of Teaching Hospital, Cairo, 
      Egypt.
FAU - Said, Fadwa
AU  - Said F
AUID- ORCID: 0000-0001-5233-7324
AD  - Clinical Pathology Department, Faculty of Medicine, Cairo University, Giza, 
      Egypt.
LA  - eng
PT  - Journal Article
DEP - 20200207
PL  - Egypt
TA  - Anemia
JT  - Anemia
JID - 101536021
PMC - PMC7033950
COIS- The authors declare that they have no conflicts of interest related to the 
      publication of this manuscript.
EDAT- 2020/02/26 06:00
MHDA- 2020/02/26 06:01
PMCR- 2020/02/07
CRDT- 2020/02/26 06:00
PHST- 2019/09/04 00:00 [received]
PHST- 2019/12/31 00:00 [accepted]
PHST- 2020/02/26 06:00 [entrez]
PHST- 2020/02/26 06:00 [pubmed]
PHST- 2020/02/26 06:01 [medline]
PHST- 2020/02/07 00:00 [pmc-release]
AID - 10.1155/2020/3041738 [doi]
PST - epublish
SO  - Anemia. 2020 Feb 7;2020:3041738. doi: 10.1155/2020/3041738. eCollection 2020.